NPACT- Naturally occuring Plant based Anticancerous Compound-Activity-Target DataBase

Compound: 2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone

TargetsGene NameGene IDCancerCell LinesIC50ED50EC50GI50RemarkReferences
KDRkinase insert domain receptor (a type III receptor tyrosine kinase)3791Colon CarcinomaHDMEC6.20 µg/mL---The results suggested that 2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone (ON-III) significantly inhibited phosphorylation of KDR in a dose-dependent manner at concentrations of 0, 2.5, 5.0, 10.0, and 20.0 g/ml; the IC50 value was 6.20 g/ml inHDMEC cells. But levels of KDR protein were unaffected after ON-III treatment.15703376
KDRkinase insert domain receptor (a type III receptor tyrosine kinase)3791Human Carcinoma xenograftsGLC-826.20 µg/mL---The results suggested that 2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone (ON-III) significantly inhibited phosphorylation of KDR in a dose-dependent manner at concentrations of 0, 2.5, 5.0, 10.0, and 20.0 g/ml; the IC50 value was 6.20 g/ml inHDMEC cells. But levels of KDR protein were unaffected after ON-III treatment.15703376
KDRkinase insert domain receptor (a type III receptor tyrosine kinase)3791Liver CarcinomaBEL-74026.20 µg/mL---The results suggested that 2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone (ON-III) significantly inhibited phosphorylation of KDR in a dose-dependent manner at concentrations of 0, 2.5, 5.0, 10.0, and 20.0 g/ml; the IC50 value was 6.20 g/ml inHDMEC cells. But levels of KDR protein were unaffected after ON-III treatment.15703376

 






Copyright © 2012. Subhash M. Agagrwal. All Rights Reserved.